Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635824 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
A Phase 3 study of PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, sponsored by Genmab.
- Active
- Registry status
- Phase 3
- Development phase
- 191
- Enrollment target
- 20
- Study locations
NCT06635824 is a Phase 3 study of PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC that is active but no longer recruiting, run by Genmab. The registered enrollment target is 191 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06635824, a Phase 3 study of PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, is active but no longer recruiting, sponsored by Genmab.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 191 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Acasunlimab
Study Locations (20)
Georgia
- University Cancer & Blood Center, LLC - Athens
- Piedmont Cancer Institute Atlanta - Atlanta
- Piedmont Cancer Institute - Sandy Springs (Atlanta) Office - Atlanta
- Piedmont Cancer Institute - Fayetteville Office - Fayetteville
- Piedmont Cancer Institute - Newnan Office - Newnan
- Piedmont Cancer Institute - Stockbridge Office - Stockbridge
Kentucky
- Baptist Health Lexington - Lexington
- Norton Cancer Institute - Louisville
- Pikeville Medical Center - Pikeville
California
- Usc Norris Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente Vallejo Medical Center - Vallejo
Florida
- Ocala Oncology Center P.L. - Ocala
- Orlando Regional Medical Center - Orlando
Nebraska
- St. Francis Hospital - Grand Island - Grand Island
- Oncology Hematology West - Omaha
Arizona
- Arizona Blood and Cancer Specialists - Tucson
Hawaii
- Kaiser Foundation Hospitals - Honolulu
Illinois
- University of Illinois - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635824
The ClinicalTrials.gov registry entry for NCT06635824 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06635824 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Georgia, Kentucky, California.
Frequently Asked Questions
What is clinical trial NCT06635824 about?
NCT06635824 is a clinical study titled "Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)". This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-...
What is the current status of trial NCT06635824?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 191 participants. The study started on 2024-11-25. Estimated completion is 2028-09-30.
What conditions does trial NCT06635824 study?
This clinical trial studies the following conditions: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC.
What interventions are being tested in trial NCT06635824?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Acasunlimab (DRUG).
Who is sponsoring clinical trial NCT06635824?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635824 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.